Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Medtronic
Express Scripts
Harvard Business School
Mallinckrodt
Dow
McKesson

Last Updated: November 22, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,108,866

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,108,866 protect, and when does it expire?

Patent 7,108,866 protects CARDIZEM LA and is included in one NDA.

This patent has ten patent family members in eight countries.

Summary for Patent: 7,108,866
Title:Chronotherapeutic diltiazem formulations and the administration thereof
Abstract:A controlled-release Galenical preparation of pharmaceutically acceptable Diltiazem including the pharmaceutically acceptable salts thereof, suitable for evening dosing every 24 hours containing from about 120 mg to about 540 mg or more (as desired) of the form of Diltiazem associated with excipients to provide controlled (sustained) release of the form of Diltiazem for providing a C.sub.max of Diltiazem in the blood at between about 10 hours and about 15 hours after administration, the preparation comprising the form of Diltiazem in oral sustained-release dosage form in which the Diltiazem is adapted to be released after administration over a prolonged period of time and exhibits when given to humans(i) a higher bioavailability when given at night compared to when given in the morning without food according to FDA guidelines or criteria and(ii) bioequivalence when given in the morning with and without food according to the same FDA guidelines or criteria.
Inventor(s): Albert; Kenneth Stephen (Mt. Kisco, NY), Maes; Paul Jose (Oakville, CA)
Assignee: Biovall Laboratories International SRL (St. Michael, BB)
Application Number:09/567,451
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,108,866
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form; Formulation;

Drugs Protected by US Patent 7,108,866

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Bausch CARDIZEM LA diltiazem hydrochloride TABLET, EXTENDED RELEASE;ORAL 021392-001 Feb 6, 2003 AB RX Yes No   Start Trial   Start Trial Y TREATMENT OF HYPERTENSION AND ANGINA PECTORIS   Start Trial
Bausch CARDIZEM LA diltiazem hydrochloride TABLET, EXTENDED RELEASE;ORAL 021392-002 Feb 6, 2003 AB RX Yes No   Start Trial   Start Trial Y TREATMENT OF HYPERTENSION AND ANGINA PECTORIS   Start Trial
Bausch CARDIZEM LA diltiazem hydrochloride TABLET, EXTENDED RELEASE;ORAL 021392-003 Feb 6, 2003 AB RX Yes No   Start Trial   Start Trial Y TREATMENT OF HYPERTENSION AND ANGINA PECTORIS   Start Trial
Bausch CARDIZEM LA diltiazem hydrochloride TABLET, EXTENDED RELEASE;ORAL 021392-004 Feb 6, 2003 AB RX Yes No   Start Trial   Start Trial Y TREATMENT OF HYPERTENSION AND ANGINA PECTORIS   Start Trial
Bausch CARDIZEM LA diltiazem hydrochloride TABLET, EXTENDED RELEASE;ORAL 021392-005 Feb 6, 2003 AB RX Yes No   Start Trial   Start Trial Y TREATMENT OF HYPERTENSION AND ANGINA PECTORIS   Start Trial
Bausch CARDIZEM LA diltiazem hydrochloride TABLET, EXTENDED RELEASE;ORAL 021392-006 Feb 6, 2003 AB RX Yes Yes   Start Trial   Start Trial Y TREATMENT OF HYPERTENSION AND ANGINA PECTORIS   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,108,866

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Canada2292247Dec 10, 1999
Canada2307547May 04, 2000

International Family Members for US Patent 7,108,866

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 430561   Start Trial
Australia 4903700   Start Trial
Canada 2292247   Start Trial
Canada 2307547   Start Trial
Canada 2566590   Start Trial
Germany 60042168   Start Trial
European Patent Office 1235562   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
AstraZeneca
Medtronic
Harvard Business School
Dow
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.